Lineage Cell Therapeutics (LCTX) Change in Accured Expenses (2010 - 2026)

Lineage Cell Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$1.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 1529.52% year-over-year to -$1.7 million; the TTM figure through Mar 2026 stood at $665000.0 (up 154.87% YoY), while the FY2025 annual figure was $2.3 million, up 235.1% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.7 million, down from $2.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.5 million in Q4 2025, with the low at -$18.9 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is -$354000.0 (2025), against an average of -$1.3 million.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses plunged 1733.66% in 2022, then surged 2435.05% in 2025.
• Lineage Cell Therapeutics' Change in Accured Expenses stood at -$1.1 million in 2022, then surged by 202.83% to $1.2 million in 2023, then plunged by 91.65% to $97000.0 in 2024, then soared by 2435.05% to $2.5 million in 2025, then sank by 169.58% to -$1.7 million in 2026.
• Business Quant data shows LCTX's Change in Accured Expenses at -$1.7 million in Q1 2026, $2.5 million in Q4 2025, and $271000.0 in Q3 2025.